JonesResearch analyst Danya Ben-Hail initiated coverage of Nuvation Bio (NUVB) with a Buy rating and $10 price target The company is focused on developing clinical stage targeted therapeutics with best in class durability and prolonged survival in lung cancer and glioma and also has an experienced management team headed by its founding CEO, Dr. David Hung, who sold Medivation to Pfizer for $14B in 2016, the analyst tells investors in a research note. JonesResearch adds it is focusing on the company’s two programs that Nuvation Bio acquired from AnHeart Therapeutics in April 2024 – ROS1 inhibitor taletrectinib and IDH1 inhibitor safusidenib – with key updates expected from both assets in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio price target lowered to $10 from $11 at H.C. Wainwright
- Nuvation Bio Reports Transformative Year in 2024
- Nuvation Bio Positioned for Growth: Buy Rating Affirmed on Strategic Moves and Promising Drug Pipeline
- Nuvation Bio files automatic mixed securities shelf
- Nuvation Bio reports Q4 EPS (15c), two estimates (12c)